William Blair analyst Margaret Kaczor has maintained their bullish stance on GKOS stock, giving a Buy rating on April 29.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Margaret Kaczor has given her Buy rating due to a combination of factors that highlight Glaukos’s promising outlook. The company’s first-quarter sales exceeded expectations, primarily driven by strong performance in iDose and international glaucoma sales. Despite some challenges, such as the local coverage determination affecting the core MIGS franchise, the management’s decision to maintain full-year revenue guidance reflects confidence in their strategic adjustments.
Furthermore, Kaczor points to several encouraging indicators, including positive month-to-month trends for iDose, increased expectations for this product, and progress in their product pipeline with minimal tariff impact. These factors, coupled with Glaukos’s efforts to meet reimbursement and commercial milestones, suggest a transformative period ahead. The recent stock pullback presents an opportunity for investors, as the company is poised for sequential growth through 2025, making it an attractive investment at its current valuation.